Register Login

Kiniksa Pharmaceuticals (KNSA)

(10% Negative) Kiniksa Pharmaceuticals International, plc (KNSA) Announces Delay in increase Development Timeline Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 28, 2025, 11:41 a.m.

    📋 Kiniksa Pharmaceuticals International, plc (KNSA) - Clinical Trial Update

    Filing Date: 2025-10-28

    Accepted: 2025-10-28 07:39:36

    Event Type: Clinical Trial Update

    Event Details:

    Kiniksa Pharmaceuticals (KNSA) Announces Clinical Trial Update Kiniksa Pharmaceuticals (KNSA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: increase, million
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process, Regulatory Timeline
    • Collaboration: Orphan Drug Designation
    • Updated Timeline: third quarter 2025, Q3 2025

    🔬 Clinical Development Pipeline (Kiniksa Pharmaceuticals International, plc):

    Product Type Development Stage Therapeutic Area Source
    KPL-387 DRUG Phase PHASE2 Pericarditis ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Pericarditis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Kiniksa Pharmaceuticals
    • CIK: 0001730430
    • Ticker Symbol: KNSA
    • Period End Date: 2025-10-28
    • Document Type: 8-K

Search

News categories